Lifeact is a short actin-binding peptide that is used to visualize filamentous actin (F-actin) 10 structures in live eukaryotic cells using fluorescence microscopy. However, this popular probe 11 has been shown to alter cellular morphology by affecting the structure of the cytoskeleton. The 12 molecular basis for such artefacts is poorly understood. Here, we determined the high-13
Introduction 25
The network of actin filaments in eukaryotic cells is involved in processes ranging from 26 intracellular trafficking to cell movement, cell division and shape control (Pollard and Cooper, 27 2009 ). It is therefore not surprising that much effort has been directed to characterize the actin 28 cytoskeleton under both physiological and pathological conditions. Numerous actin-visualizing 29 compounds were developed to enable this. These include small molecules, labelled toxins, 30 recombinant tags, as well as actin-binding proteins and peptides (see (Melak et al., 2017) for a 31 detailed review). However, using these molecules to study actin in vivo often alters the 32 properties of actin filaments to such an extent that normal homeostasis of the cytoskeleton is 33 impaired. Since these side effects cannot be avoided, it is important to know their molecular 34 basis in order to be able to adequately interpret the experimental data. 35
Phalloidin and jasplakinolide are cyclic peptides derived from the death cap mushroom 36
Amanita phalloides and marine sponge Jaspis johnstoni (Crews et al., 1986; Lynen and 37 Wieland, 1938), respectively. They bind specifically to F-actin, and when fused to a fluorescent 38 probe their derivatives allow visualization of the cell cytoskeleton by fluorescence microscopy 39 (Melak et al., 2017) . However, both molecules strongly stabilize F-actin and shift the cellular 40 actin equilibrium, largely limiting their use in live cell imaging (Bubb et al., 2000; Dancker et 41 al., 1975) . Recent cryo-EM studies from our group and others have uncovered how phalloidin 42 and jasplakinolide affect the structure of F-actin and described the potential limitations of their 43 use (Mentes et al., 2018; Merino et al., 2018a; Pospich et al., 2019) . 44
The development of various fluorescent proteins provided new ways of visualizing the 45 actin cytoskeleton. A simple and popular technique compatible with live cell imaging is to 46 express actin fused to GFP-like proteins (Ballestrem et al., 1998) . However, such actin chimeras 47 often interfere with the normal functionality of the cytoskeleton in a way that results in 48 experimental artefacts (Aizawa et al., 1997; Nagasaki et al., 2017 ). An alternative to GFP-actin 49 is to fuse GFP to actin-binding proteins, such as utrophin (Burkel et al., 2007; Lin et al., 2011) 50 or Arabidopsis fimbrin (Sheahan et al., 2004) and synthetic affimers that bind actin (Kost et al., 51 1998; Lopata et al., 2018) . These actin filament markers have been successfully used in a variety 52 of cell types and organisms (Melak et al., 2017;  Montes-Rodriguez and Kost, 2017; Spracklen 53 et al., 2014) . 54
The most recent development is an F-actin binding nanobody called Actin-Chromobody 55 that claims to have a minimal effect on actin dynamics and no notable effect on cell viability 56 (Schiavon et al., 2019) . However, the binding of the Actin-Chromobody to actin has not yet 57 been characterized at molecular level, leaving the true extent of possible side effects open. 58
Results and Discussion 88

Structure of the Lifeact-F-actin complex 89
Based on previous studies (Mentes et al., 2018; Merino et al., 2018b; Pospich et al., 2019) , we 90 know that phalloidin stabilizes actin filaments. When it is added during polymerization, the 91 nucleotide binding pocket is occupied with an ADP and Pi and the D-loop is in the open 92 conformation (Pospich et al., 2019) . We therefore polymerized actin in the presence of 93 phalloidin and added an excess of Lifeact to the formed filaments in order to fully decorate the 94 filaments with Lifeact. We then determined the structure of this complex by cryo-EM ( Fig. 1 , 95 Table 1 ). The average resolution of the reconstruction was 3.5 Å, with local areas reaching 3.0 96 Å (Fig. S1 ), which allowed us to build an atomic model in which we could position most of the 97 side chains. We could clearly identify densities corresponding to ADP, Mg 2+ and Pi in the 98 nucleotide-binding pocket of actin ( Fig. 1A ) and a density corresponding to phalloidin at the 99 expected position (Mentes et al., 2018; Merino et al., 2018a; Pospich et al., 2019) in the center 100 of the filament (Fig. 1A) . Lifeact was well resolved and we could unambiguously fit 16 out of 101 17 amino acids into the density (Fig. 1, Fig. S2 ). 102
The peptide folds as an α-helix and spans two consecutive actin subunits of the same 103 strand of the filament (Fig. 1A, B ). The binding pocket is formed by the tip of the D-loop of the 104 lower subunit (M47) and SD1 of the upper subunit, where the N-terminal region of Lifeact is 105 almost locked in by the protruding D25 of actin ( Fig. 1B) . Although Lifeact is in general a 106 hydrophilic peptide, it contains a hydrophobic patch formed by the side chains of V3, L6, I7, 107 F10 and I13 which all orient to one side. This hydrophobic patch interacts with a hydrophobic 108 groove on the surface of F-actin which comprises M44, M47, Y143, I345 and L349. F10 of 109
Lifeact is deeply buried in this pocket (Fig. 1C ). Interestingly and contrary to what we have 110 seen before in samples co-polymerized with phalloidin (Pospich et al., 2019) , the D-loop is in 111 its closed conformation ( Fig. S3 ). A comparison between the Lifeact-F-actin-ADP-Pi -112 phalloidin-structure with that of phalloidin-stabilized F-actin-ADP-Pi (Pospich et al., 2019) 113 shows that direct interactions between Lifeact and the D-loop of F-actin are only possible if the 114 D-loop is in its closed conformation (Movie S1). Specifically, I13 of Lifeact interacts with M47 115 of F-actin, stabilizing the closed D-loop conformation in F-actin. This suggests that Lifeact has 116 a higher affinity to F-actin-ADP, where the D-loop is in the closed conformation, than to 117 phalloidin-stabilized F-actin-ADP-Pi, where the D-loop has to be first moved from the open to 118 the closed conformation. Indeed, Kumari et al. (Kumari et al., 2019) showed in a 119 complementary study that the affinity of Lifeact is three to four times higher for F-actin-ADP 120 compared to F-actin-ADP-Pi. 121
and Lifeact, we conclude that hydrophobicity as well as shape complementarity are important 140 for efficient Lifeact binding to F-actin. 141
Our structure suggests that actin D25 acts as an N-terminal cap for the helix of Lifeact 142 and a mutation of actin D25 to tyrosine would affect this interaction and mutating L349 of actin 143 to methionine would impair its crucial interaction with Lifeact F10. Indeed, actin-rich structures 144 were also absent when Lifeact-mCherry was expressed in cells with the D25Y or the L349M 145 actin variant ( Fig. 2C, D) , indicating that actin D25 and Lifeact F10 are important for Lifeact 146 binding. 147
To study the effect of Lifeact WT and variants on yeast viability we overexpressed 148 Lifeact-MBP fusions under a strong galactose promoter and analyzed their toxicity in a yeast 149 growth phenotype assay. Consistent with a previously reported study (Courtemanche et al., 150 2016), we observed that the overexpression of Lifeact-MBP caused cell toxicity ( Fig. 2E ). 151
However, mutagenesis of I13 to alanine improved, and L6 to lysine and F10 to alanine fully 152 restored yeast growth. Altogether, these results demonstrate the importance of shape 153 complementarity as well as hydrophobicity at the Lifeact-actin interface. 154
Lifeact mutations increase its affinity to F-actin 156
Despite these specific interactions between Lifeact and F-actin, the peptide binds to F-actin 157 only with micromolar affinity (Riedl et al., 2008) . A higher affinity would provide a stronger 158 signal-to-noise ratio, decreasing the background during live imaging, and allowing lower 159 expression levels of the peptide to be used during such experiments. We therefore attempted to 160 increase the affinity of Lifeact to F-actin by structure-guided in silico design using 161
RosettaScripts (Fleishman et al., 2011) based on our atomic model. The simulation output 162 suggested several possible mutations after residue 12 of Lifeact (Fig. 3A) . The mutation E16R 163 was especially promising. It was predicted to add an additional interaction with the D-loop and 164 an electrostatic interaction with E167 of actin ( Fig. 3B ). Indeed, this variant showed an 165 increased affinity for F-actin as judged by cosedimentation assays (Fig. 3C , D). Although we 166 could not observe density for E17 of Lifeact in our density map, we also created and tested a 167 E17K variant of Lifeact which should similarly create an additional interaction with E167 of 168 actin and thereby increase the affinity of the peptide. In line with the prediction, E17K Lifeact-169 MBP variants showed an increased affinity for F-actin ( Fig. 3C, D) . Together, these 170 modifications show that based on our atomic model, Lifeact can be optimized by mutations to 171 increase its binding to actin. with that of F-actin-cofilin (Tanaka et al., 2018) , it becomes obvious that the binding site of cofilin overlaps with that of Lifeact ( Fig. 4A) . Notably, the same is true for myosin, which 190 interacts with the same position on the actin surface ( Fig. 4B ) (Ecken et al., 2016) . We therefore 191 performed in vitro competition actin binding assays with human cofilin-1, the motor domain of 192 human non-muscle myosin 2C isoform (NM2C), and Lifeact. Lifeact successfully decreased 193 cofilin and myosin binding in a dose-dependent manner ( Fig. 4C-F) . As a negative control, we 194 performed a similar competition assay with tropomyosin that binds to a different region of actin 195 In our laboratory, we study two bacterial toxins that interact with F-actin. One is Pseudomonas 205 aeruginosa ExoY, a toxin that becomes a potent nucleotidyl cyclase upon interaction with F-206 actin (Belyy et al., 2016) . After activation, the toxin generates a supraphysiologic amount of 207 cGMP and cAMP that impedes cell signaling. It was previously demonstrated that the 208 mutagenesis of D25 in actin abolishes ExoY binding to F-actin (Belyy et al., 2018) . The same 209 actin mutation also prevents Lifeact binding, we therefore hypothesize that Lifeact and ExoY 210 have overlapping binding sites. 211
The second toxin is the 30 kDa C-terminal fragment of Photorhabdus luminescens 212 TccC3 (TccC3HVR), which is the effector domain of the large Tc toxin complex PTC3. Once 213 it is translocated into the cell by the injection machinery of PTC3, TccC3HVR acts as an ADP-214 ribosyltransferase that modifies actin at T148 (Lang et al., 2010) . This leads to uncontrolled 215 actin polymerization, clustering, and finally to cell death due to cytoskeletal collapse. T148 is 216 located in close proximity to the Lifeact binding site, therefore the actin binding site of 217 TccC3HVR and Lifeact might overlap. 218
To understand whether Lifeact competes with the binding of ExoY, we first performed 219 a cosedimentation assay with ExoY, F-actin and different concentrations of Lifeact. In 220 agreement with our hypothesis, we observed a decrease of ExoY binding to F-actin in the 221 presence of Lifeact while the Lifeact F10A mutant did not impair formation of the ExoY-F-222 actin complex ( Fig. 5A, B) . 223
We then ADP-ribosylated F-actin by TccC3HVR in the presence of Lifeact. In our 224 experimental setup, 3 µM of WT Lifeact was already sufficient to decrease the level of ADP 225 ribosylation by a factor of two, while in the control reaction 100 µM of F10A Lifeact did not 226 decrease the level of ADP-ribosylation at all ( Fig. 5C, D) . This experiment strongly supports 227 the hypothesis that TccC3HVR and Lifeact bind to the same region of F-actin. 228
Encouraged by these in vitro results, we decided to test whether expressing Lifeact in 229 mammalian cells would protect them from the TccC3HVR toxin. We therefore expressed either 230 mCherry-tagged WT Lifeact, Lifeact F10A, Lifeact E17K, or mCherry-tagged actin as a 231 negative control in adherent HEK 293T cells. We then intoxicated the cells with PTC3 and 232 observed the effect of the injected TccC3HVR. Our control cells expressing actin and cells 233 expressing the F-actin binding-incompetent F10A Lifeact showed rapid cytoskeletal collapse 234 and accompanying overall shrinkage ( Fig. 5E , F). However, the toxic effect of TccC3HVR was 235 significantly reduced in cells that expressed WT Lifeact or the binding-competent E17K 236 mutant. Thus, Lifeact has anti-toxin properties and despite its effects on the cytoskeleton, it has 237 the potential to be used as a precursor for the development of anti-toxin drugs. with the background information that is needed to make a properly informed decision on 247 whether to use Lifeact in an experiment. Furthermore, we have demonstrated that Lifeact 248 competes with actin-binding toxins such as ExoY and TccC3HVR, and partially counteracts 249 the intoxication of cells by PTC3 toxin. This paves the way for the development of Lifeact-250 based anti-toxin drugs. 251
Plasmids, bacteria and yeast strains, growth conditions 253
The complete list of used oligonucleotides, constructions and strains can be found in the 254 Supplementary data. E. coli strains were grown in LB medium supplemented with ampicillin 255 (100 µg/ml) or kanamycin (50 µg/ml). S. cerevisiae were grown on rich YPD medium or on 256 synthetic defined medium (Yeast nitrogen base, Difco) containing galactose or glucose and 257 supplemented if required with uracil, histidine, leucine, tryptophan, or adenine. S. cerevisiae 258 strains were transformed using the lithium-acetate method (Daniel Gietz and Woods, 2002). 259
Yeast actin mutagenesis was performed as described previously . Yeast 260 viability upon Lifeact-MBP overexpression under the galactose promoter was analyzed by a 261 drop test: 5-fold serial dilutions of cell suspensions were prepared from overnight agar cultures 262 by normalizing OD600 measurements, then spotted onto agar plates and incubated for 2-3 days 263 at 30 °C. Analysis of protein expression in yeast was performed following the described 264 protocol (Kushnirov, 2000) : Rabbit skeletal muscle a-actin was purified as described previously (Merino et al., 284 2018b) and stored in small aliquots at -80 °C. 285
Human cofilin-1 was purified from E. coli cells using previously described method 286 (Carlier et al., 1997) . In short, Rosetta DE3 E. coli cells were transformed with the 1855 287
plasmid. An overnight culture derived from a single colony was diluted into 2 L of LB media 288 to OD600 0.06 and grown at 37 °C. When OD600 reached 0.7, the cells were cooled to 30 °C and 289 of the lysate was heated for 10 minutes at 80 °C, then cooled down to 4 °C and centrifuged. 308
The supernatant was mixed 1:1 with buffer H (20 mM sodium acetate buffer pH 4.5, 100 mM 309 NaCl, 5 mM MgCl2 and 2 mM EGTA). The precipitate was collected and incubated for 1 h 310 with buffer I (10 mM Bis-Tris pH 7, 100 mM NaCl). The renatured protein was applied to a 311 HiTrap Q anion exchange column and eluted by a linear gradient of 100 mM to 1 M NaCl in 312 buffer I. Tropomyosin-containing fractions were pooled and stored at -80 °C. 313
The motor domain of non-muscular myosin-2C (MYH14, isoform 2 from H. sapiens) 314 consisting of amino acids 1-799 was purified as described previously (Ecken et al., 2016) 315 Tcc3HVR, the ADP-ribosyltransferase domain of the Photorhabdus luminescens TccC3 316 protein (amino acids 679 -960) was purified as described previously (Roderer et al., 2019) . 317
The TcdA1 and TcdB1-TccC3 components of the Photorhabdus luminescens PTC3 toxin were 318 expressed and purified as described previously (Gatsogiannis et al., 2016) . 319
Cryo-EM sample preparation, data acquisition, and processing 321
Actin was polymerized by incubation in F-buffer in the presence of a twofold molar excess of 322 phalloidin for 30 minutes at room temperature and further overnight at 4 °C. The next day, actin 323 filaments were pelleted using a TLA-55 rotor for 30 minutes at 150.000 g at 4 °C and 324 resuspended in F-buffer. 5 minutes before plunging, F-actin was diluted to 6 µM and mixed Cosedimentation assays were performed in 20 µl volumes by first incubating F-actin with the 388 specified proteins for 5 minutes at room temperature, then centrifuging at 150,000 g using the 389 TLA-55 or TLA120.1 rotor for 30 minutes at 4 °C. For the competition assays, Lifeact peptide 390 was added to the mixture at the specified concentrations. After centrifugation, aliquots of the 391 supernatant and resuspended pellet fractions were separated by SDS-PAGE using 4-15% 392 gradient TGX gels (Bio-Rad) and analyzed by densitometry using Image Lab software (Bio-393 Rad). 
